Meister Keith A. sold $61.1M of ILMN (indirect holdings)

Meister Keith A. sold 280,091 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $218.12 ($212.97–$222.44, $61.09M total) across 21 trades over 2026-11-09 to 2026-11-11.

Original reporting
SEC EDGAR · Meister Keith A.
Published Nov 12, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
high confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishMed
01

Why it matters

The disclosed sale may prompt short‑term price weakness, but long‑term fundamentals remain unchanged.

02

Market read

Direct insider sell of over $60M is a material event for traders monitoring ILMN.

03

What to watch

Potential tax planning or diversification needs of the director may drive the transaction.

Relevance 6/10Novelty 8/10Timing: today

Background

SEC Form 4 filing discloses a director's open‑market sale of Illumina shares.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Director Meister Keith A. sold 280,091 shares for $61.1M, reducing his stake to 208,826 shares.

Expected impact

downward pressure as the market prices in the insider sell

Evidence & confidence

The $61M sale represents a significant reduction in holdings by a senior insider, which traders often interpret as a negative signal.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

Primarily U.S. market effect; no notable regional ripple.

Limited to investors tracking Illumina and insider activity.

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Illumina, Inc.

    US‑listed biotech firm (NASDAQ: ILMN).

  • Meister Keith A.

    Director of Illumina who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.